

- Bangalore, S., Kamalakkannan, G., Parkar, S., & Messerli, F. H. (2007). Fixed-dose combinations improve medication compliance: a meta-analysis. *The American journal of medicine*, 120(8), 713-719.
- Basit, A., Riaz, M., & Fawwad, A. (2012). Glimepiride: evidence-based facts, trends, and observations. *Vascular health and risk management*, 8, 463.
- Becquemont, L. (2009). Pharmacogenomics of adverse drug reactions: practical applications and perspectives. *Pharmacogenomics*, 10(6), 961-969.
- Best, J. H., Hoogwerf, B. J., Herman, W. H., Pelletier, E. M., Smith, D. B., Wenten, M., & Hussein, M. A. (2011). Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database. *Diabetes care*, 34(1), 90-95.
- Blank, R., LaSalle, J., Reeves, R., Maroni, J., Tarasenko, L., & Sun, F. (2005). Single-Pill Therapy in the Treatment of Concomitant Hypertension and Dyslipidemia (The Amlodipine/Atorvastatin Gemini Study). *The Journal of Clinical Hypertension*, 7(5), 264-273.
- Brancati, F. L., Whelton, P. K., Randall, B. L., Neaton, J. D., Stamler, J., & Klag, M. J. (1997). Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. *Jama*, 278(23), 2069-2074.